Skip to content
buyModerate cluster of 15

Vensana Capital I GP, LLC bought $2.6M of SGP

owner at SpyGlass Pharma, Inc.. 165,000 shares at an average of $16.00, traded Feb 9, 2026, filed Feb 10, 2026.

Conviction score
50
Value
$2.6M
165,000 shares
Holdings after
3,310,619
+5% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    10% owner
    +12
  • Trade size
    $2.6M at market
    +25
  • Relative to holdings
    Holdings up 5%
    +3
  • Price context
    No price history yet
    0
  • Cluster
    15 insiders buying within 14 days
    +15
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0
  • Outside holder
    A 10% owner who is not an officer or director
    -5

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -5.1%, 3m -13.3%, 6m -10.7%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

SGPOct 9, 2026 · close 24.92
Since filing Feb 10, 2026: -10.5%SPY +13.3% · excess -23.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001193125-26-045028, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Feb 9, 2026CConversion
Common Stockindirect: See footnote
+1,690,230--1,690,230Feb 10, 2026
Feb 9, 2026CConversion
Common Stockindirect: See footnote
+548,067--2,238,297Feb 10, 2026
Feb 9, 2026CConversion
Common Stockindirect: See footnote
+548,067--2,786,364Feb 10, 2026
Feb 9, 2026CConversion
Common Stockindirect: See footnote
+359,255--3,145,619Feb 10, 2026
Feb 9, 2026POpen-market purchase
Common Stockindirect: See footnote
+165,000$16.00$2.6M3,310,619Feb 10, 2026
Feb 9, 2026CConversion
Series B Preferred Stockderivativeindirect: See Footnote
-9,689,922--0Feb 10, 2026
Feb 9, 2026CConversion
Series C-1 Preferred Stockderivativeindirect: See Footnote
-3,142,015--0Feb 10, 2026
Feb 9, 2026CConversion
Series C-2 Preferred Stockderivativeindirect: See Footnote
-3,142,015--0Feb 10, 2026
Feb 9, 2026CConversion
Series D Preferred Stockderivativeindirect: See Footnote
-2,059,573--0Feb 10, 2026

Related signals

Other insiders at SpyGlass Pharma, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
50Moderate
SGPbuy 15
SpyGlass Pharma, Inc.
Forest Baskett
owner
$15M
937,500 shares
+18%
58Moderate
SGPbuy 15
SpyGlass Pharma, Inc.
Ali Behbahani
director, owner
$15M
937,500 shares
+18%
50Moderate
SGPbuy 15
SpyGlass Pharma, Inc.
Carmen Chang
owner
$15M
937,500 shares
+18%
50Moderate
SGPbuy 15
SpyGlass Pharma, Inc.
Anthony A. Florence Jr.
owner
$15M
937,500 shares
+18%
65Notable
SGPbuy 15
SpyGlass Pharma, Inc.
Bilal Arshad Khan
director
$2.2M
135,000 shares
+2477%
60Notable
SGPbuy 15
SpyGlass Pharma, Inc.
Ra Capital Management, L.p.
director, owner
$59M
3,690,000 shares
+146%
50Moderate
SGPbuy 15
SpyGlass Pharma, Inc.
Mohamad Makhzoumi
owner
$15M
937,500 shares
+18%
50Moderate
SGPbuy 15
SpyGlass Pharma, Inc.
Edward T Mathers
owner
$15M
937,500 shares
+18%
50Moderate
SGPbuy 15
SpyGlass Pharma, Inc.
New Enterprise Associates 17, L.P.
owner
$15M
937,500 shares
+18%
58Moderate
SGPbuy 15
SpyGlass Pharma, Inc.
Geoffrey B Pardo
director
$5.0M
312,500 shares
+17%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Vensana Capital I GP, LLC bought $2.6M of SGP | InsiderTell